Telomir Pharmaceuticals, Inc. (TELO)
NASDAQ: TELO · Real-Time Price · USD
1.450
+0.030 (2.11%)
At close: Apr 28, 2026, 4:00 PM EDT
1.470
+0.020 (1.38%)
Pre-market: Apr 29, 2026, 5:41 AM EDT
Telomir Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Cash & Equivalents | 7.29 | 1.27 | 0 | 0 | - |
| Cash & Short-Term Investments | 7.29 | 1.27 | 0 | 0 | - |
| Cash Growth | 475.51% | 102753.86% | -13.25% | - | - |
| Prepaid Expenses | 0.05 | 0.06 | 0 | - | - |
| Other Current Assets | - | - | 0.43 | 0.05 | - |
| Total Current Assets | 7.34 | 1.32 | 0.44 | 0.05 | - |
| Long-Term Deferred Charges | - | - | 4.34 | - | - |
| Accounts Payable | 0.54 | 0.59 | 0.71 | 0.4 | 0.02 |
| Accrued Expenses | 0.42 | - | - | - | - |
| Short-Term Debt | 0.47 | 0.09 | 0.63 | 0.58 | 0.12 |
| Total Current Liabilities | 1.43 | 0.68 | 1.34 | 0.99 | 0.14 |
| Additional Paid-In Capital | 46.92 | 31.24 | 17.5 | 0.06 | 0.06 |
| Retained Earnings | -41.01 | -30.6 | -14.06 | -0.99 | -0.14 |
| Comprehensive Income & Other | - | - | - | - | -0.06 |
| Total Liabilities & Equity | 7.34 | 1.32 | 4.77 | 0.05 | - |
| Total Debt | 0.47 | 0.09 | 0.63 | 0.58 | 0.12 |
| Net Cash (Debt) | 6.81 | 1.17 | -0.63 | -0.58 | -0.12 |
| Net Cash Growth | 480.96% | - | - | - | - |
| Net Cash Per Share | 0.22 | 0.04 | -0.02 | -0.02 | - |
| Filing Date Shares Outstanding | 34.38 | 29.76 | 29.61 | 27.1 | - |
| Total Common Shares Outstanding | 34.38 | 29.76 | 28.61 | 26.83 | - |
| Working Capital | 5.91 | 0.64 | -0.9 | -0.94 | -0.14 |
| Book Value Per Share | 0.17 | 0.02 | 0.12 | -0.03 | - |
| Tangible Book Value | 5.91 | 0.64 | 3.44 | -0.94 | -0.14 |
| Tangible Book Value Per Share | 0.17 | 0.02 | 0.12 | -0.03 | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.